The financial results of BioLineRx for FY23, including total revenues of $4.8 million and an EPS of $(0.06), provide a mixed signal to investors. The revenue figure might be seen positively if it aligns with or exceeds market expectations. However, a negative EPS indicates a loss per share, which could be a concern. The impact on the stock price would depend on how these figures compare to analyst expectations and the broader market context.